{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:54:47Z","timestamp":1775804087328,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.051","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T21:48:50Z","timestamp":1526766530000},"page":"3967-3975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16\/18 in girls and young women: Results from a phase III randomized trial"],"prefix":"10.1016","volume":"36","author":[{"given":"Luis","family":"Rivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pornthep","family":"Chanthavanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airi","family":"P\u00f5der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.V.","family":"Suryakiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Jastorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.051_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr."},{"key":"10.1016\/j.vaccine.2018.05.051_b0010","first-page":"E116","article-title":"Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage","volume":"56","author":"Gabutti","year":"2015","journal-title":"J Prev Med Hyg."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.05.051_b0015","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.05.051_b0025","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2015.10.055","article-title":"The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations","volume":"33","author":"Safadi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0030","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0035","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","article-title":"Global epidemiology of capsular group W meningococcal disease (1970\u20132015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex","volume":"34","author":"Mustapha","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.051_b0045","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.051_b0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.05.051_b0055","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2017 global summary. Available from <http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules> [accessed 30 August 2017]."},{"key":"10.1016\/j.vaccine.2018.05.051_b0060","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/INF.0000000000000795","article-title":"Pertussis across the globe: recent epidemiologic trends from 2000 to 2013","volume":"34","author":"Tan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.05.051_b0065","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.cmi.2016.01.003","article-title":"Immunization against pertussis in adolescents and adults","volume":"22","author":"Esposito","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.05.051_b0070","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S0950268812003093","article-title":"Perplexities of pertussis: recent global epidemiological trends and their potential causes","volume":"142","author":"Jackson","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.05.051_b0075","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.051_b0080","first-page":"241","article-title":"WHO position paper, May 2017","volume":"92","author":"Human papillomavirus vaccines","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.05.051_b0085","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2018.05.051_b0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vaccine.2018.05.051_b0095","unstructured":"World Health Orgaization. WHO recommendations for routine immunization - summary tables. March 2017. Available from <http:\/\/www.who.int\/immunization\/policy\/Immunization_routine_table 1.pdf?ua=1> [accessed 4 October 2017]."},{"key":"10.1016\/j.vaccine.2018.05.051_b0100","doi-asserted-by":"crossref","unstructured":"Bernstein HH, Bocchini JA, Jr. The need to optimize adolescent immunization. Pediatrics 2017;139. https:\/\/doi.org\/10.1542\/peds.2016-4186.","DOI":"10.1542\/peds.2016-4186"},{"key":"10.1016\/j.vaccine.2018.05.051_b0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12889-016-2845-z","article-title":"Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review","volume":"16","author":"Gallagher","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2018.05.051_b0110","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.vaccine.2012.03.063","article-title":"Factors associated with HPV vaccine uptake in teenage girls: a systematic review","volume":"30","author":"Kessels","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2018.05.051_b0120","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.051_b0125","unstructured":"European Medicines Agency. Nimenrix. Summary of product characteristics. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf> [accessed 7 February 2017]."},{"key":"10.1016\/j.vaccine.2018.05.051_b0130","unstructured":"European Medicines Agency. Cervarix. Summary of product characteristics. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000721\/WC500024632.pdf> [accessed 28 August 2017]."},{"key":"10.1016\/j.vaccine.2018.05.051_b0135","unstructured":"Boostrix. Highights of prescribing information. Available from: <https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/UCM152842.pdf> [accessed 4 December 2017]."},{"key":"10.1016\/j.vaccine.2018.05.051_b0140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2014.09.064","article-title":"Immunogenicity and reactogenicity of Infanrix when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix and Pediarix","volume":"33","author":"Leonardi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jadohealth.2009.11.205","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women","volume":"46","author":"Garcia-Sicilia","year":"2010","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.05.051_b0150","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.051_b0155","unstructured":"Inadvertent misadministration of meningococcal conjugate vaccine \u2013 United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006;55:1016\u20137."},{"key":"10.1016\/j.vaccine.2018.05.051_b0160","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0165","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/JCM.20.4.772-774.1984","article-title":"Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum","volume":"20","author":"Camargo","year":"1984","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.051_b0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","article-title":"A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera","volume":"11","author":"Melville-Smith","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2018.05.051_b0175","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.05.051_b0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF02097184","article-title":"Acellular pertussis vaccine in adults: adverse reactions and immune response","volume":"6","author":"Granstrom","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.051_b0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(87)90289-4","article-title":"Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA)","volume":"103","author":"Karpinski","year":"1987","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.05.051_b0190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.051_b0195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0200","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.vaccine.2017.06.007","article-title":"Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: optimal age for vaccination","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0205","author":"Rivera","year":"2018"},{"key":"10.1016\/j.vaccine.2018.05.051_b0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12879-015-1138-y","article-title":"Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial","volume":"15","author":"Borja-Tabora","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.051_b0220","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/21645515.2015.1091908","article-title":"Interactions of conjugate vaccines and co-administered vaccines","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.051_b0225","unstructured":"European Medicines Agency. Menveo. Summary of product characteristics. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001095\/WC500090147.pdf> [accessed 4 December 2017]."},{"key":"10.1016\/j.vaccine.2018.05.051_b0230","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.vaccine.2010.11.057","article-title":"Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration","volume":"29","author":"Weston","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0235","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-3476(96)70152-X","article-title":"Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants","volume":"129","author":"Schmitt","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2018.05.051_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.vaccine.2010.10.025","article-title":"A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults","volume":"29","author":"Booy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.051_b0245","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1542\/peds.2005-1759","article-title":"Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents","volume":"117","author":"Pichichero","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.05.051_b0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.1996.03530250041024","article-title":"Efficacy of acellular pertussis vaccine in early childhood after household exposure","volume":"275","author":"Schmitt","year":"1996","journal-title":"JAMA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T05:37:11Z","timestamp":1604295431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":49,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306716"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16\/18 in girls and young women: Results from a phase III randomized trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}